Skip to content
    RPRX
    Earnings call· Mar 2025(Q1 FY25)

    Royalty Pharma Q1 FY25 earnings call RPRX

    May 8, 2025 Source

    Executive summary

    Royalty Pharma Q1 FY25 — Strong Portfolio Performance Drives Raised Full-Year Guidance and Accelerated Share Repurchases

    Royalty Pharma delivered a strong Q1 FY25, driven by robust portfolio performance and strategic capital allocation. The company raised its full-year guidance for portfolio receipts, reflecting underlying strength and a favorable FX tailwind. Management actively returned capital to shareholders through significant share repurchases while continuing to invest in attractive royalty assets and advancing its pipeline.

    Highlights

    5

    • Royalty receipts grew by 12% in Q1 FY25, reflecting the strength of the diversified portfolio.

    • Portfolio receipts grew by 17% to $839 million in Q1 FY25, exceeding expectations.

    • Full-year 2025 portfolio receipts guidance raised to $2.975 billion - $3.125 billion, representing 6% to 12% growth.

    • Repurchased $723 million of shares in Q1 FY25, part of an authorized $3 billion program, leveraging a dynamic capital allocation framework.

    • Expanded development-stage pipeline with a new Phase III R&D funding collaboration for litifilimab with Biogen, a potential blockbuster.

    Concerns

    4

    • Potential cuts to NIH funding

    • Potential tariffs on pharmaceutical products

    • Uncertainty regarding potential arbitration with Vertex over CF franchise royalties

    • Impact of Medicare Part D redesign on portfolio receipts

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year 2025 Portfolio Receipts
    $2.975 billion to $3.125 billion
    high materiality
    High
    Full-year 2025 Portfolio Receipts Growth
    around 6% to 12%
    high materiality
    High
    Second Quarter 2025 Portfolio Receipts
    $700 million and $725 million
    medium materiality
    High
    Second Quarter 2025 Portfolio Receipts Growth
    15% to 19%
    medium materiality
    High
    Full-year 2025 Milestones and other contractual receipts
    approximately $60 million
    low materiality
    High
    Full-year 2025 Operating and Professional Costs
    approximately 10% of portfolio receipts
    medium materiality
    High
    Full-year 2025 Interest Paid
    around $260 million
    medium materiality
    High
    Internalization Transaction Close
    current quarter
    high materiality
    High
    Share Repurchase Program
    up to $2 billion
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Royalty Receipts
    Represents recurring cash flow, driven by underlying strength of diversified portfolio.
    Cystic Fibrosis franchise: strong performanceTrelegy: strong performanceXtandi: strong performanceVoranigo: royalties acquired in 2024
    		$788 million12%——
    Milestones and Other Contractual Receipts
    More variable component of portfolio receipts, included a larger payment this quarter.
    Airsupra: $27 million milestone payment
    		$51 million———

    Operational metrics

    18
    Royalty Receipts Growth
    12%YoY
    Q1 FY25

    Reflects recurring cash flow and strength of diversified portfolio.

    Portfolio Receipts Growth
    17%YoY
    Q1 FY25

    Top line growth, includes milestone payments.

    Portfolio Receipts
    $839 million
    Q1 FY25

    Top line, includes royalty and milestone receipts.

    Operating and Professional Costs as % of Portfolio Receipts
    12.1%
    Q1 FY25

    Includes $33 million of one-time payments related to MorphoSys development funding bonds sale.

    Net Interest Paid
    $127 million
    Q1 FY25

    Reflected semi-annual timing of interest payment schedule (Q1 and Q3 payments). Included interest on $1.5 billion incremental debt raised in June 2024.

    Portfolio Cash Flow
    $611 million
    Q1 FY25

    Equivalent to adjusted EBITDA less net interest paid. Reflects high cash conversion.

    Capital Deployment on Royalty Transactions
    $101 million
    Q1 FY25

    Deployed on value-creating royalty transactions.

    Share Repurchases Executed
    $723 million
    Q1 FY25

    Reduced weighted average share count by 19 million shares compared to prior year. Part of a dynamic capital allocation framework.

    Total Capital Returned to Shareholders
    $850 million
    Q1 FY25

    Record for Royalty Pharma, includes share repurchases and dividends.

    Dividend Growth
    mid-single-digit growth
    Q1 FY25

    Increased in line with commitment.

    Cash and Equivalents
    $1.1 billion
    Q1 FY25 end

    Includes $511 million upfront cash from MorphoSys development funding bonds sale in January.

    Investment-Grade Debt Outstanding
    $7.8 billion
    Q1 FY25 end
    Leverage (Total Debt to EBITDA)
    3x
    Q1 FY25 end
    Undrawn Financial Capacity from Revolver
    $1.8 billion
    Q1 FY25 end
    MorphoSys Development Funding Bonds Sale Proceeds
    $511 million
    January

    Upfront cash received, accounted for as an asset sale, not included in portfolio receipts.

    Biotech Capital Required
    $1 trillion
    Next decade

    Estimated capital required by unprofitable biopharma (biotechs) to move pipelines along.

    Tariff Impact on Royalties
    no meaningful impact
    Future

    Expected potential tariffs to be paid upstream of royalty-bearing sale.

    Patent Expiry / LOE Impact
    —
    FY25

    Impact of Promacta generics and biosimilar Tysabri considered in full-year guidance scenarios.

    Industry KPIs

    6
    MetricValueDetails
    EPS revenue guidanceFY25 Portfolio Receipts: $2.975B-$3.125B (6-12% growth)USD
    Pricing policy impactMedicare Part D redesign
    Pipeline clinical milestonesMultiple
    Regulatory approvals filingsMultiple
    Clinical trial efficacy safety dataPositive
    Business development capacity deal appetiteRobust deal pipeline

    Deals & partnerships

    3
    BiogenR&D funding collaboration for litifilimab in lupusup to $250 millionover 6 quarters

    Supports advancement of litifilimab (Phase III development for SLE and CLE). Phase III results expected in 2026 and 2027.

    MLX BiosciencesAcquisition of royalty interest in ecopipam for Tourette syndrome$49 million upfront and up to $44 million in contingent regulatory milestones

    Acquired at the start of 2024. Positive Phase III data reported in February 2025.

    External ManagerAcquisition of external manager

    Will provide an update after it closes.

    Risks & headwinds

    4
    Potential cuts to NIH fundingFuture

    Proposed cut of about $20 million (from $47 million to $27 million) by Trump administration

    Mitigation: Company sees this as a potential opportunity to provide alternative funding to biotechs; industry organizing to present position to government.

    Potential tariffs on pharmaceutical productsFuture

    No meaningful impact on royalties expected

    Mitigation: Tariffs expected to be paid upstream of royalty-bearing sale, not directly impacting Royalty Pharma's receipts.

    Uncertainty regarding potential arbitration with Vertex over CF franchise royaltiesOngoing

    Not quantified, but company feels strongly about its position

    Mitigation: Company expects Vertex CF franchise to remain a major long-term contributor regardless of royalty rate outcomes.

    Impact of Medicare Part D redesign on portfolio receiptsFY25

    Considered in FY25 guidance scenarios

    Mitigation: Guidance accounts for a range of scenarios.

    What to watch in Q2 FY25

    5

    External Manager Internalization Transaction Close

    Q2 FY25
    Currenton track to close
    TargetClosed

    Why it matters

    Expected to deliver multiple benefits for shareholders and impact operating costs.

    We also announced the acquisition of our external manager, which we expect to deliver multiple benefits for shareholders, and we're on track to close the transaction in the current quarter.

    Q&A highlights

    5

    How has policy uncertainty impacted deal-making and risk evaluation? Any updates on Vertex CF arbitration?

    The pipeline remains robust despite policy uncertainty, which is not impacting the opportunity set for alternative capital. No update on Vertex CF arbitration, but the company feels strongly about its position.

    “Obviously, there's a lot of policy uncertainty but that's not really impacting our opportunity set, and we think that's going to show through for the remainder of the year.”

    asked by Hardik Parikh · answered by Christopher Hite

    1 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 Financial Performance

    Royalty Pharma reported a successful start to 2025, with royalty receipts growing 12% and total portfolio receipts increasing 17% to $839 million in Q1. This performance was driven by the strength of its diversified portfolio, including cystic fibrosis franchise, Trelegy, and Xtandi, and the acquisition of Voranigo royalties. The company also received a $27 million milestone payment on Airsupra.

    02

    Dynamic Capital Allocation and Shareholder Returns

    The company implemented a dynamic capital allocation framework, allowing for flexibility in addressing share price valuation and pursuing royalty acquisitions. In Q1, Royalty Pharma repurchased $723 million of shares, contributing to a record $850 million returned to shareholders, while also increasing its dividend in line with mid-single-digit growth commitment.

    03

    Pipeline Expansion and Regulatory Updates

    Royalty Pharma expanded its development-stage pipeline through a new R&D funding collaboration with Biogen for litifilimab, a potential blockbuster therapy for lupus. Encouraging regulatory and clinical news included FDA and EC approval of TREMFYA in Crohn's and ulcerative colitis, positive Phase III results for ecopipam in Tourette syndrome, and Roche advancing trontinemab into Phase III for Alzheimer's disease.

    04

    Robust Investment Environment and Policy Impact

    Despite policy uncertainties, the investment environment for alternative forms of capital remains very strong, with Royalty Pharma's in-depth reviews increasing significantly. The company sees potential opportunities arising from the need for alternative funding sources for biotechs, especially given concerns about proposed NIH funding cuts and the capital requirements of the biopharma R&D ecosystem.

    05

    Tariff Impact and Internalization Transaction

    Management does not expect any meaningful impact from potential tariffs on its royalties, as tariffs are typically paid upstream of the royalty-bearing sale. The company is also on track to close the internalization transaction of its external manager in the current quarter, which is expected to deliver multiple benefits for shareholders.

    AI-generated summary of the company’s earnings call. Not investment advice.